https://www.merck.com/news/merck-announces-pivotal-keynote-671-trial-meets-dual-primary-endpoint-of-overall-survival-os-in-resectable-stage-ii-iiia-or-iiib-non-small-cell-lung-cancer-nsclc/
0
0
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC) - Merck
+ 113 more
10/10/23 at 10:30am
Organization
Merck.com
Authors
Details
67 words
Summarize
Pharmaceuticals & Biotech Business & Industrial News KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival Merck Resectable Stage II NSCLC Merck KEYTRUDA Keytruda IIIB Non-Small Cell Lung Cancer Adopt PD-1 NYSE neoadjuvant U.S.
KEYTRUDA® (pembrolizumab) is the first anti-PD-1 therapy to demonstrate statistically significant improvement in OS as a neoadjuvant and adjuvant treatment versus pre-operative chemotherapy for NSCLC Merck (NYSE: MRK), known as MSD outside of the United State…
Create an account or login to join the discussion